India · Delayed Price · Currency is INR Caplin Point Laboratories Earnings Call Transcripts
Fiscal Year 2026
-
Q3 FY26 saw double-digit revenue and profit growth, margin expansion, and strong cash flow. US and Latin America drive future growth, with new product launches, regulatory approvals, and major CapEx investments supporting long-term expansion.
-
Revenue and profit margins grew strongly in H1 FY26, with PAT up 21.6% and EBITDA margin expanding. Expansion in the U.S., Mexico, and Latin America, along with robust cash reserves, positions the company for continued growth and potential acquisitions.
-
Q1 FY2026 delivered 11.7% revenue growth and 20.7% PAT growth, driven by strong Latin America and U.S. performance, robust margins, and a focus on asset-light models. Management projects continued double-digit growth, with new product launches and CapEx supporting future expansion.
Fiscal Year 2025
-
Revenue grew 15% to INR 2,034 crore and PAT rose 17% to INR 541 crore, with record margins and strong liquidity. U.S. and Latin America expansions, new product launches, and disciplined capital allocation underpin a focus on sustainable, high-quality growth.
-
Nine-month FY25 revenue and profits surpassed FY23 full-year levels, driven by strong U.S. and LATAM growth, robust margins, and a strategic shift to own-label launches in the U.S. Expansion into Mexico and Chile, new product approvals, and internal funding support a positive multi-year outlook.
-
Q2 FY25 saw 17.8% revenue growth year-over-year, with strong contributions from core, new, and sterile segments. Strategic focus remains on LatAm and U.S. expansion, specialty products, and vertical integration, all supported by robust cash flows and internal funding.
-
Q1 FY25 saw 17% revenue and 20% PAT growth, with gross margin rising to 59.6% and strong cash reserves. U.S. and Latin America drove performance, Caplin Steriles' contribution increased, and major CapEx is planned for injectables and API facilities.